

MERCK

By the numbers

BioReliance® Viral Clearance services

Working with a partner with proven experience can accelerate your drug development process and provide peace of mind.

35

years performing viral clearance studies



3

sites around the globe



models from which to choose: standard, hybrid, or Provisio™ clearance



520

clients worldwide

17,300+

studies performed




60K

liters of virus per year



4M

and counting 96-well microplates



Hello

你好

10

languages

420

years of combined experience process scientists & study directors



25%

of team are PhDs



3

month formal training program

Viral clearance studies are a critical requirement to provide safety data prior to IND and BLA filings. Studies are individually-designed to investigate and illustrate the capacity of the manufacturing process to inactivate or remove potential virus contaminants.

Learn more at SigmaAldrich.com/viralclearance

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the vibrant M, BioReliance, and Provisio are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

MK_PS8497EN 37872 11/2021

The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.

BioReliance®

Pharma & Biopharma
Manufacturing &
Testing Services